Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease caused by mutations in the HTT gene, which encodes the huntingtin protein. Although the mutant protein is known to form protein aggregates leading to neuronal toxicity, the loss of wild-type (WT) huntingtin functions – which include axonal transport of brain-derived neurotrophic factor (BDNF) – might also play a role in HD. To elucidate this, Folma Buss and colleagues used primary fibroblasts from homozygous mutant Htt140Q/140Q knock-in mice, HTT knockdown human HeLa cells and heterozygous HD patient fibroblasts that express one WT copy and one mutant copy (with a 180Q expansion) of HTT. They analysed different steps of protein secretion and found that the complete loss of WT huntingtin in mouse fibroblasts and HeLa cells impaired vesicle transport from the endoplasmic reticulum (ER) to the Golgi complex. Although one copy of WT protein was sufficient to maintain the secretory pathway in human HD fibroblasts, the distances for cargo transport in the secretory pathway are extremely large in neurons; therefore, a slight decrease in the efficiency of delivery might contribute to the reduced BDNF secretion in HD. These results have important implications for therapies that aim to reduce huntingtin levels. Page 1335
Loss of WT huntingtin impairs ER-to-Golgi transport
Loss of WT huntingtin impairs ER-to-Golgi transport. Dis Model Mech 1 December 2014; 7 (12): e1202. doi:
Download citation file:
Advertisement
Cited by
Interviews with Biologists @ 100 conference speakers

Explore our interviews with keynote speakers from the Biologists @ 100 conference, hosted to celebrate our publisher’s 100th anniversary, where we discuss climate change and biodiversity with Hans-Otto Pörtner and Jane Francis, health and disease with Charles Swanton and emerging technologies with Manu Prakash and Jennifer Lippincott-Schwartz.
A new perspective on disease research
DMM publishes perspectives – peer-reviewed articles that provide expert analysis of a topic important to the disease research community. Read our collection from authors presenting new or potentially controversial ideas or hypotheses, to help address future challenges and forge new directions.
Read & Publish Open Access publishing: what authors say

We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
Fast & Fair peer review

Our sister journal Biology Open has recently launched the next phase of their Fast & Fair peer review initiative: offering high-quality peer review within 7 working days. To learn more about BiO’s progress and future plans, read the Editorial by Daniel Gorelick, or visit the Fast & Fair peer review page.
History of our journals

As our publisher, The Company of Biologists, turns 100 years old, read about DMM’s history and explore the journey of each of our sister journals: Development, Journal of Cell Science, Journal of Experimental Biology and Biology Open.
Other journals from
The Company of Biologists